Alembic Pharma

Why is Alembic Pharmaceuticals Ltd. falling/rising?

As of 13-Aug, Alembic Pharmaceuticals Ltd. is facing a stock price decline to 831.40, down 1.17%, due to underperformance relative to its sector, a trend reversal after previous gains, and decreased investor participation. Despite strong debt servicing ability and profit growth, negative sentiment persists amid longer-term underperformance.

As of 13-Aug, Alembic Pharmaceuticals Ltd. is experiencing a decline in its stock price, currently at 831.40, which reflects a change of -9.85 or -1.17%. This downward movement can be attributed to several factors highlighted in the source data. <BR><BR>Firstly, the stock has underperformed its sector by 1.15% today, indicating a weaker performance relative to its peers. Additionally, the stock has seen a trend reversal, falling after three consecutive days of gains, suggesting a shift in market sentiment. The delivery volume has also decreased significantly, with a drop of 32.02% compared to the 5-day average, indicating falling investor participation, which often correlates with declining stock prices.<BR><BR>Moreover, while the stock is trading above its longer-term moving averages (20-day, 50-day, 100-day, and 200-day), it is below the 5-day moving average, which can signal short-term weakness. <BR><BR>In terms of broader performance, the stock has a year-to-date decline of 1.98% and a one-year decline of 11.89%, contrasting with a positive return of 5.41% over the last three years. This longer-term underperformance may contribute to negative investor sentiment.<BR><BR>Despite these challenges, the company maintains a strong ability to service its debt, with a low Debt to EBITDA ratio of 1.28 times, and its profits have risen by 27.1% over the past year, suggesting some underlying strength. However, these positive factors have not been sufficient to counteract the current downward pressure on the stock price.

Should I buy, sell or hold Alembic Pharmaceuticals Ltd.?

Which are the latest news on Alembic Pharma?

Are Alembic Pharmaceuticals Ltd. latest results good or bad?

Alembic Pharmaceuticals Ltd.'s latest results show strong revenue growth with a 25.66% year-on-year increase, but a 14.62% decline in net profit quarter-on-quarter and ongoing margin pressures indicate challenges in profitability. Investors should consider these mixed signals when evaluating the company's performance.

Alembic Pharmaceuticals Ltd.'s latest results present a mixed picture. In Q1 FY27, the company reported a net profit of ₹173.07 crore, which reflects a decline of 14.62% quarter-on-quarter but a growth of 12.11% year-on-year. This indicates that while the company is experiencing some year-over-year improvement, it is facing challenges in maintaining profitability on a sequential basis.<BR><BR>On the revenue front, net sales reached ₹2,149.77 crore, marking a robust increase of 16.35% quarter-on-quarter and an impressive 25.66% year-on-year growth. This strong sales performance suggests that Alembic is successfully expanding its market presence and product offerings.<BR><BR>However, the operating margin, which improved to 15.44% from the previous quarter, remains below the levels achieved in the same quarter last year, indicating ongoing pressure on profitability. Additionally, the return on equity (ROE) of 10.96% is below the industry average, raising concerns about the company's capital efficiency.<BR><BR>Overall, while Alembic Pharmaceuticals shows strong revenue growth, the decline in net profit and margin pressures suggest that the company is navigating a challenging operational environment. Investors may need to weigh these factors carefully when assessing the company's performance.

What does Alembic Pharma do?

Alembic Pharmaceuticals Ltd. is a small-cap company that manufactures and markets generic pharmaceutical products globally. As of March 2026, it reported net sales of 1,848 Cr and a net profit of 203 Cr, with a market cap of INR 14,566 Cr.

Overview:<BR>Alembic Pharmaceuticals Ltd. manufactures and markets generic pharmaceutical products globally and operates within the Pharmaceuticals & Biotechnology industry as a small-cap company.<BR><BR>History:<BR>Alembic Pharmaceuticals Ltd. was incorporated on June 16, 2010, as a wholly owned subsidiary of Alembic Ltd. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1,848 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 203 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 14,566 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 20.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 1.51% <BR>Debt-Equity: 0.22 <BR>Return on Equity: 12.93% <BR>Price to Book: 2.53 <BR><BR>Contact Details:<BR>Address: Alembic Road, Vadodara Gujarat: 390003 <BR>Phone: 91-0265-2280550 <BR>Email: apl.investors@alembic.co.in <BR>Website: http://www.alembicpharmaceuticals.com

How big is Alembic Pharma?

As of 10th June, Alembic Pharmaceuticals Ltd. has a market capitalization of 14,566.00 Cr, with recent net sales of 7,344.90 Cr and a net profit of 674.76 Cr.

As of 10th June, Alembic Pharmaceuticals Ltd. has a market capitalization of 14,566.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Alembic Pharmaceuticals reported Net Sales of 7,344.90 Cr and a Net Profit of 674.76 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 5,190.94 Cr and Total Assets of 7,606.90 Cr.

Who are in the management team of Alembic Pharma?

The management team of Alembic Pharma includes Chirayu R Amin (Chairman & CEO), Pranav Amin and Shaunak Amin (Managing Directors), Rajkumar Baheti (CFO), and Manisha Saraf (Company Secretary). The board also features several independent directors, contributing to the company's strategic direction and regulatory compliance.

The management team of Alembic Pharma includes the following key individuals:<BR><BR>1. **Chirayu R Amin** - Chairman & CEO<BR>2. **Pranav Amin** - Managing Director<BR>3. **Shaunak Amin** - Managing Director<BR>4. **Rajkumar Baheti** - Director (Finance) & CFO<BR>5. **Manisha Saraf** - Company Secretary & Compliance Officer<BR><BR>Additionally, the board features several independent directors:<BR>- **Pranav N Parikh**<BR>- **K G Ramanathan**<BR>- **Paresh Saraiya**<BR>- **Archana Hingorani**<BR>- **Ashok Barat**<BR>- **Jai S Diwanji**<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulatory standards.

Who are the peers of the Alembic Pharma?

Alembic Pharma's peers include Granules India, Caplin Point Lab, Natco Pharma, and Shilpa Medicare, among others. Granules India leads with a 1-year return of 45.45%, while Alembic Pharma has a return of -25.33%.

Peers: The peers of Alembic Pharma are Granules India, Caplin Point Lab, Cohance Life, Natco Pharma, Jubilant Pharmo, Concord Biotech, Alivus Life, Marksans Pharma, Viyash Scientifi, and Shilpa Medicare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Granules India, Caplin Point Lab, Natco Pharma, Concord Biotech, Alivus Life, Marksans Pharma, and Alembic Pharma, while Average management risk is found at Cohance Life and Viyash Scientifi. Good growth is noted at none of the peers, while Below Average growth is seen at all peers except for Shilpa Medicare, which has Below Average growth as well. Excellent capital structure is present in Granules India, Caplin Point Lab, Cohance Life, Natco Pharma, Alembic Pharma, Concord Biotech, Alivus Life, and Marksans Pharma, while Average capital structure is noted at Jubilant Pharmo and Below Average at Viyash Scientifi and Shilpa Medicare.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Granules India at 45.45%, while Cohance Life has the lowest at -57.75%. Alembic Pharma's 1-year return of -25.33% is better than Cohance Life's but worse than Granules India's. Additionally, Cohance Life, Natco Pharma, Jubilant Pharmo, Concord Biotech, and Shilpa Medicare have negative six-month returns.

Is Alembic Pharma technically bullish or bearish?

As of December 1, 2025, Alembic Pharma's technical outlook is bearish, driven by negative indicators such as a bearish MACD, moving averages, and KST, with no signs of bullish momentum from the RSI.

As of 1 December 2025, the technical trend for Alembic Pharma has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include a bearish MACD on the weekly chart, bearish moving averages on the daily chart, and a bearish KST on the weekly chart. Both Bollinger Bands and the monthly MACD are mildly bearish, indicating a continuation of negative momentum. The RSI shows no signals on both weekly and monthly time frames, suggesting a lack of bullish momentum. Overall, the technical outlook remains negative.

How has been the historical performance of Alembic Pharma?

Alembic Pharma has shown consistent growth in net sales, reaching 6,672.08 Cr in March 2025, but profit after tax declined to 581.14 Cr. Total assets increased to 7,606.90 Cr, while cash flow from operating activities significantly dropped to 87.00 Cr, indicating potential cash management challenges.

Answer:<BR>The historical performance of Alembic Pharma shows a trend of increasing net sales and total operating income over the years, with net sales reaching 6,672.08 Cr in March 2025, up from 6,228.63 Cr in March 2024 and 5,652.62 Cr in March 2023. The total expenditure has also risen, amounting to 5,663.84 Cr in March 2025, compared to 5,295.27 Cr in March 2024. Operating profit, excluding other income, was 1,008.24 Cr in March 2025, reflecting a steady increase from 933.36 Cr in March 2024. However, profit after tax showed a slight decline to 581.14 Cr in March 2025 from 616.80 Cr in March 2024. The company's total assets increased to 7,606.90 Cr in March 2025, up from 6,275.94 Cr in March 2024, while total liabilities also rose to 7,606.90 Cr in March 2025, compared to 6,275.94 Cr in March 2024. Cash flow from operating activities decreased significantly to 87.00 Cr in March 2025 from 803.00 Cr in March 2024, indicating a shift in cash generation capabilities.<BR><BR>Breakdown:<BR>Alembic Pharma's financial performance has demonstrated a consistent growth trajectory in net sales, which increased from 5,305.79 Cr in March 2022 to 6,672.08 Cr in March 2025. This growth in sales has been accompanied by rising total operating income, which reached 6,672.08 Cr in March 2025. Despite this increase, the total expenditure also rose, leading to an operating profit of 1,008.24 Cr in March 2025, an improvement from the previous year. However, profit after tax saw a decrease to 581.14 Cr in March 2025, down from 616.80 Cr in March 2024. The company's total assets grew significantly to 7,606.90 Cr in March 2025, reflecting a robust asset base, while total liabilities increased correspondingly. The cash flow from operating activities, however, faced a notable decline, indicating potential challenges in cash management despite the overall growth in sales and assets.

Is Alembic Pharma overvalued or undervalued?

As of November 6, 2025, Alembic Pharma is considered very attractive and undervalued compared to peers, with a PE ratio of 28.37 and a PEG ratio of 0.00, indicating strong growth potential despite recent stock performance declines.

As of 6 November 2025, Alembic Pharma's valuation grade has moved from attractive to very attractive, indicating a significant positive shift in its valuation outlook. The company is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 28.37, an EV to EBITDA of 27.19, and a Price to Book Value of 0.34, which highlight its potential for growth relative to its market price.<BR><BR>In comparison to its peers, Alembic Pharma's valuation stands out; for instance, Sun Pharma has a PE ratio of 35.02 and Divi's Lab is at 79.09, both categorizing them as expensive. Additionally, while Alembic Pharma's PEG ratio is 0.00, indicating no growth premium, competitors like Cipla and Dr. Reddy's Labs have PEG ratios of 1.25 and 2.15, respectively, suggesting that Alembic may offer better value. Despite a recent decline in stock performance relative to the Sensex over the past year, the company's strong fundamentals and attractive valuation metrics position it favorably in the market.

When is the next results date for Alembic Pharma?

The next results date for Alembic Pharma is 04 November 2025.

The next results date for Alembic Pharma is scheduled for 04 November 2025.

Who are the top shareholders of the Alembic Pharma?

The top shareholders of Alembic Pharma include Nirayu Limited with 35.64%, mutual funds holding 9.2%, foreign institutional investors at 3.94%, and DSP Midcap Fund as the largest public shareholder with 4.6%. Individual investors own 7.07% of the total shares.

The top shareholders of Alembic Pharma include the promoters, who hold the majority of the shares. The promoter with the highest holding is Nirayu Limited, which owns 35.64% of the company. Additionally, mutual funds collectively hold 9.2% through 21 different schemes, while foreign institutional investors (FIIs) account for 3.94% with 151 FIIs involved. The highest public shareholder is DSP Midcap Fund, holding 4.6%. Individual investors also have a stake, representing 7.07% of the total shares.

Has Alembic Pharma declared dividend?

Yes, Alembic Pharmaceuticals Ltd. has declared a 550% dividend, amounting to ₹11 per share, with an ex-date of July 15, 2024. While recent performance shows mixed returns, the company has demonstrated positive total returns over the 2-year (81.26%) and 5-year (20.15%) periods.

Alembic Pharmaceuticals Ltd. has declared a 550% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 550%<BR>- Amount per share: 11<BR>- Ex-date: 15 Jul 24<BR><BR>Dividend Yield: 1.13%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -9.25%, with no dividend return, resulting in a total return of -9.25%.<BR><BR>Over the past year, the price return was 10.07%, with a dividend return of 1.23%, leading to a total return of 11.3%.<BR><BR>In the 2-year period, the price return was 78.15%, with a dividend return of 3.11%, culminating in a total return of 81.26%.<BR><BR>For the 3-year period, the price return was 34.58%, with a dividend return of 4.03%, resulting in a total return of 38.61%.<BR><BR>In the last 4 years, the price return was 3.58%, with a dividend return of 4.30%, giving a total return of 7.88%.<BR><BR>Over the past 5 years, the price return was 15.37%, with a dividend return of 4.78%, leading to a total return of 20.15%.<BR><BR>Overall, Alembic Pharmaceuticals has declared a significant dividend, and while the recent performance shows mixed returns, the longer-term total returns indicate a positive trend, particularly over the 2-year and 5-year periods.